In:
Russian Journal of Allergy, Farmarus Print Media, Vol. 19, No. 2 ( 2022-06-06), p. 259-269
Abstract:
On February 19, 2022, a working meeting of experts on the problem of atopic dermatitis was held in Moscow under the chairmanship of the Director of the State Scientific Center for Dermatovenereology and Cosmetology of the Ministry of Health of Russia, Doctor of Medical Sciences, Professor, Corresponding Member of the Russian Academy of Sciences A.A. Kubanov. Also in attendance was the Academician of the Russian Academy of Sciences, Chief Freelance Childrens Specialist in Preventive Medicine, Head of the Research Institute of Pediatrics and Childrens Health of the Central Clinical Hospital of the Russian Academy of Sciences of the Ministry of Science, and Higher Education of the Russian Federation, Doctor of Medical Sciences, Professor, Academician of the Russian Academy of Sciences, L.S. Namazova-Baranova, and also the Deputy Director for Clinical Work ― Chief Physician of the Federal State Budgetary Institution SSC Institute of Immunology FMBA of Russia Doctor of Medical Sciences, Professor N.I. Ilyina. The meeting raised germane issues of providing medical care, reducing the burden of the disease, and improving the quality of life of patients with atopic dermatitis. New possibilities and principles of systemic therapy in patients with moderate and severe atopic dermatitis were discussed. We analyzed data on a new representative of the small molecule class the selective Janus kinase 1 inhibitor, upadacitinib, which was registered in the Russian Federation in June 2021. This analysis aimed to determine its place in atopic dermatitis therapy algorithms and the possibility of the impact of its use as a therapy on the quality of life of patients in relation to the burden of diseases. The article has been published in several journals simultaneously with permission from authors and publishers. The parallel publication is available here: Capabilities of atopic dermatitis systemic therapy with selective immunosuppressors: resolution of the experts workshop of dermatology profile. Pediatric pharmacology. 2022;19(2):209211. DOI: https://doi.org/10.15690/pf.v19i2.2424
Type of Medium:
Online Resource
ISSN:
2686-682X
,
1810-8830
Language:
Unknown
Publisher:
Farmarus Print Media
Publication Date:
2022
